Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02058147
Registration number
NCT02058147
Ethics application status
Date submitted
6/02/2014
Date registered
7/02/2014
Date last updated
9/05/2017
Titles & IDs
Public title
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Query!
Scientific title
A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
Query!
Secondary ID [1]
0
0
2013-003131-30
Query!
Secondary ID [2]
0
0
EFC12404
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
LixiLan-O
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Insulin glargine/lixisenatide Fixed Ratio Combination
Treatment: Drugs - Insulin glargine (HOE901)
Treatment: Drugs - Lixisenatide (AVE0010)
Treatment: Drugs - Metformin
Experimental: Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) - FRC once daily (QD) for 30 weeks. Dose individually adjusted.
Active Comparator: Insulin Glargine - Insulin glargine QD for 30 weeks. Dose individually adjusted.
Active Comparator: Lixisenatide - Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
Treatment: Drugs: Insulin glargine/lixisenatide Fixed Ratio Combination
Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
Treatment: Drugs: Insulin glargine (HOE901)
Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
Treatment: Drugs: Lixisenatide (AVE0010)
Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
Treatment: Drugs: Metformin
Pharmaceutical form: Tablet; Route of administration: Oral administration.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in HbA1c From Baseline to Week 30
Query!
Assessment method [1]
0
0
Primary outcome was to test superiority of FRC versus Lixisenatide and non-inferiority versus Insulin glargine.
Change in HbA1c was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [1]
0
0
Baseline, Week 30
Query!
Secondary outcome [1]
0
0
Percentage of Participants With HbA1c <7.0% or =6.5% at Week 30
Query!
Assessment method [1]
0
0
Participants without Week 30 value for HbA1c were counted as non-responders.
Query!
Timepoint [1]
0
0
Week 30
Query!
Secondary outcome [2]
0
0
Change in Plasma Glucose Excursion From Baseline to Week 30
Query!
Assessment method [2]
0
0
Plasma glucose excursion = 2-hour postprandial plasma glucose (PPG) value minus plasma glucose value obtained 30 minutes prior to the start of meal and before investigational medicinal product (IMP) administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 30 value. Missing data was imputed using last observation carried forward (LOCF).
Query!
Timepoint [2]
0
0
Baseline, Week 30
Query!
Secondary outcome [3]
0
0
Change in Body Weight From Baseline to Week 30
Query!
Assessment method [3]
0
0
Change in body weight was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [3]
0
0
Baseline, Week 30
Query!
Secondary outcome [4]
0
0
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 30
Query!
Assessment method [4]
0
0
Change in FPG was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [4]
0
0
Baseline, Week 30
Query!
Secondary outcome [5]
0
0
Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30
Query!
Assessment method [5]
0
0
Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.
Query!
Timepoint [5]
0
0
Baseline, Week 30
Query!
Secondary outcome [6]
0
0
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Week 30
Query!
Secondary outcome [7]
0
0
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] = 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
Query!
Assessment method [7]
0
0
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of =70 mg/dL (3.9 mmol/L).
Query!
Timepoint [7]
0
0
Baseline up to Week 30
Query!
Secondary outcome [8]
0
0
Average Daily Insulin Glargine Dose at Week 30
Query!
Assessment method [8]
0
0
The analysis included scheduled measurements obtained up to the date of last injection of the IMP, including those obtained after introduction of rescue therapy.
Query!
Timepoint [8]
0
0
Week 30
Query!
Secondary outcome [9]
0
0
Change in 2-Hour Postprandial Plasma Glucose (PPG) From Baseline to Week 30
Query!
Assessment method [9]
0
0
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 30 value. Missing data was imputed using LOCF.
Query!
Timepoint [9]
0
0
Baseline, Week 30
Query!
Secondary outcome [10]
0
0
Percentage of Participants Reaching HbA1c <7.0% at Week 30 With No Documented Symptomatic Hypoglycemia (PG = 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
Query!
Assessment method [10]
0
0
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of =70 mg/dL (3.9 mmol/L). The analysis included all HbA1c measurements at Week 30, including those obtained after the IMP discontinuation or the introduction of rescue medication.
Query!
Timepoint [10]
0
0
Baseline up to Week 30
Query!
Secondary outcome [11]
0
0
Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period
Query!
Assessment method [11]
0
0
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) was performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >8%.
Query!
Timepoint [11]
0
0
Baseline up to Week 30
Query!
Secondary outcome [12]
0
0
Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year
Query!
Assessment method [12]
0
0
Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of = 70 mg/dL (3.9 mmol/L).
Query!
Timepoint [12]
0
0
First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Documented Symptomatic Hypoglycemia
Query!
Assessment method [13]
0
0
Documented symptomatic hypoglycemia was an event during which symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of = 70 mg/dL (3.9 mmol/L).
Query!
Timepoint [13]
0
0
First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Severe Symptomatic Hypoglycemia
Query!
Assessment method [14]
0
0
Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not have been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk of injury to themselves or others.
Query!
Timepoint [14]
0
0
First dose of study drug up to 1 day after the last dose administration (median treatment exposure: 211 days)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Participants with type 2 diabetes mellitus diagnosed for at least 1 year before the
screening visit, treated for at least 3 months prior to visit 1 with metformin alone
or metformin and a second oral anti-diabetic treatment that could be a sulfonylurea, a
glinide, a sodium glucose co-transporter-2 inhibitor or a di-peptidyl peptidase 4
(DPP-4) inhibitors, and who were not adequately controlled with this treatment.
- Signed written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- HbA1c at screening visit:
- less than 7.5% or more than 10% for participants previously treated with
metformin alone,
- less than 7.0% or more than 9% for participants previously treated with metformin
and a second oral anti-diabetic treatment.
- Pregnancy or lactation, women of childbearing potential with no effective
contraceptive method.
- Use of oral glucose-lowering agents other than those stated in the inclusion criteria
or any injectable glucose-lowering agents during the 3 months before screening.
- Previous Treatment with insulin (except for short-term treatment due to intercurrent
illness including gestational diabetes, at the discretion of the trial physician).
- History of discontinuation of a previous treatment with a glucagon-like peptide
(GLP-1) receptor agonist (GLP-1 RA) due to safety/tolerability issue or lack of
efficacy.
- Participant who previously participated in any clinical trial with lixisenatide or the
insulin glargine/lixisenatide fixed ratio combination or had previously received
lixisenatide.
- Any contraindication to metformin use, according to local labeling.
- Use of weight loss drugs within 3 months prior to screening visit.
- Within the last 6 months prior to screening visit: history of stroke, myocardial
infarction, unstable angina, or heart failure requiring hospitalization. Planned
coronary, carotid or peripheral artery revascularisation procedures to be performed
during the study period.
- History of pancreatitis (unless pancreatitis was related to gallstones and
cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a
previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.
- Personal or immediate family history of medullary thyroid cancer (MTC) or genetic
conditions that predispose to MTC (e.g, multiple endocrine neoplasia syndromes).
- Uncontrolled or inadequately controlled hypertension (systolic blood pressure above
180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.
- At screening visit, Body Mass Index (BMI) less than or equal to 20 or above 40 kg/m^2.
- At screening visit amylase and/or lipase more than 3 times the upper limit of the
normal (ULN) laboratory range.
- At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more
than 3 ULN.
- At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).
Exclusion Criteria for randomization at the end of the screening period:
- HbA1c less than 7% or above 10%;
- Fasting Plasma glucose above 250 mg/dL (13.9 mmol/L);
- Metformin maximal tolerated dose less than 1500 mg/day;
- Amylase and/or lipase more than 3 ULN.
The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1170
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 036005 - Box Hill
Query!
Recruitment hospital [2]
0
0
Investigational Site Number 036001 - Camperdown
Query!
Recruitment hospital [3]
0
0
Investigational Site Number 036006 - Kippa Ring
Query!
Recruitment hospital [4]
0
0
Investigational Site Number 036007 - Logan Central
Query!
Recruitment postcode(s) [1]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [2]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
0
0
4021 - Kippa Ring
Query!
Recruitment postcode(s) [4]
0
0
4114 - Logan Central
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Montana
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nebraska
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nevada
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Hampshire
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Jersey
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Mexico
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New York
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
North Carolina
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Ohio
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Oregon
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Pennsylvania
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
South Carolina
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
South Dakota
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Tennessee
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Texas
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Utah
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Virginia
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Washington
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Wisconsin
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Brussels
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Brussel
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Leuven
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Kelowna
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Toronto
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Vancouver
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
Osorno
Query!
Country [44]
0
0
Chile
Query!
State/province [44]
0
0
Puerto Varas
Query!
Country [45]
0
0
Chile
Query!
State/province [45]
0
0
Santiago
Query!
Country [46]
0
0
Chile
Query!
State/province [46]
0
0
Talagante
Query!
Country [47]
0
0
Chile
Query!
State/province [47]
0
0
Temuco
Query!
Country [48]
0
0
Czech Republic
Query!
State/province [48]
0
0
Beroun
Query!
Country [49]
0
0
Czech Republic
Query!
State/province [49]
0
0
Ceske Budejovice
Query!
Country [50]
0
0
Czech Republic
Query!
State/province [50]
0
0
Horovice
Query!
Country [51]
0
0
Czech Republic
Query!
State/province [51]
0
0
Koprivnice
Query!
Country [52]
0
0
Czech Republic
Query!
State/province [52]
0
0
Pardubice
Query!
Country [53]
0
0
Czech Republic
Query!
State/province [53]
0
0
Plzen
Query!
Country [54]
0
0
Czech Republic
Query!
State/province [54]
0
0
Praha 10
Query!
Country [55]
0
0
Czech Republic
Query!
State/province [55]
0
0
Praha 2
Query!
Country [56]
0
0
Czech Republic
Query!
State/province [56]
0
0
Praha 5
Query!
Country [57]
0
0
Czech Republic
Query!
State/province [57]
0
0
Praha 9 - Klanovice
Query!
Country [58]
0
0
Czech Republic
Query!
State/province [58]
0
0
Trutnov
Query!
Country [59]
0
0
Czech Republic
Query!
State/province [59]
0
0
Ujezd U Brna
Query!
Country [60]
0
0
Czech Republic
Query!
State/province [60]
0
0
Vsetin
Query!
Country [61]
0
0
Denmark
Query!
State/province [61]
0
0
Aarhus C
Query!
Country [62]
0
0
Denmark
Query!
State/province [62]
0
0
Horsens
Query!
Country [63]
0
0
Denmark
Query!
State/province [63]
0
0
Kolding
Query!
Country [64]
0
0
Denmark
Query!
State/province [64]
0
0
København Nv
Query!
Country [65]
0
0
Denmark
Query!
State/province [65]
0
0
København S
Query!
Country [66]
0
0
Denmark
Query!
State/province [66]
0
0
Viborg
Query!
Country [67]
0
0
Estonia
Query!
State/province [67]
0
0
Paide
Query!
Country [68]
0
0
Estonia
Query!
State/province [68]
0
0
Pärnu
Query!
Country [69]
0
0
Estonia
Query!
State/province [69]
0
0
Tallinn
Query!
Country [70]
0
0
Estonia
Query!
State/province [70]
0
0
Viljandimaa
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Corbeil Essonnes
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
La Rochelle Cedex
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Pierre Benite
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Venissieux
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Berlin
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Dortmund
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Dresden
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Hamburg
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Neumünster
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Balatonfüred
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Budapest
Query!
Country [82]
0
0
Hungary
Query!
State/province [82]
0
0
Komárom
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Nagykanizsa
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Szeged
Query!
Country [85]
0
0
Hungary
Query!
State/province [85]
0
0
Szekesfehervar
Query!
Country [86]
0
0
Hungary
Query!
State/province [86]
0
0
Sátoraljaújhely
Query!
Country [87]
0
0
Hungary
Query!
State/province [87]
0
0
Zalaegerszeg
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Bologna
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Catanzaro
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Milano
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Napoli
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Roma
Query!
Country [93]
0
0
Latvia
Query!
State/province [93]
0
0
Riga
Query!
Country [94]
0
0
Latvia
Query!
State/province [94]
0
0
Sigulda
Query!
Country [95]
0
0
Lithuania
Query!
State/province [95]
0
0
Jonava
Query!
Country [96]
0
0
Lithuania
Query!
State/province [96]
0
0
Kaunas
Query!
Country [97]
0
0
Lithuania
Query!
State/province [97]
0
0
Kedainiai
Query!
Country [98]
0
0
Lithuania
Query!
State/province [98]
0
0
Panevezys
Query!
Country [99]
0
0
Lithuania
Query!
State/province [99]
0
0
Utena
Query!
Country [100]
0
0
Lithuania
Query!
State/province [100]
0
0
Vilnius
Query!
Country [101]
0
0
Mexico
Query!
State/province [101]
0
0
Aguascalientes
Query!
Country [102]
0
0
Mexico
Query!
State/province [102]
0
0
Cuernavaca
Query!
Country [103]
0
0
Mexico
Query!
State/province [103]
0
0
Guadalajara
Query!
Country [104]
0
0
Mexico
Query!
State/province [104]
0
0
Monterrey
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Zapopan
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Bialystok
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Krakow
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Lodz
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Szczecin
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Warszawa
Query!
Country [111]
0
0
Poland
Query!
State/province [111]
0
0
Zory
Query!
Country [112]
0
0
Romania
Query!
State/province [112]
0
0
Bucharest
Query!
Country [113]
0
0
Romania
Query!
State/province [113]
0
0
Bucuresti
Query!
Country [114]
0
0
Romania
Query!
State/province [114]
0
0
Cluj Napoca
Query!
Country [115]
0
0
Romania
Query!
State/province [115]
0
0
Hunedoara
Query!
Country [116]
0
0
Romania
Query!
State/province [116]
0
0
Iasi
Query!
Country [117]
0
0
Romania
Query!
State/province [117]
0
0
Oradea
Query!
Country [118]
0
0
Romania
Query!
State/province [118]
0
0
Targu Mures
Query!
Country [119]
0
0
Romania
Query!
State/province [119]
0
0
Timisoara
Query!
Country [120]
0
0
Russian Federation
Query!
State/province [120]
0
0
Moscow
Query!
Country [121]
0
0
Russian Federation
Query!
State/province [121]
0
0
Penza
Query!
Country [122]
0
0
Russian Federation
Query!
State/province [122]
0
0
Petrozavodsk
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Saint-Petersburg
Query!
Country [124]
0
0
Russian Federation
Query!
State/province [124]
0
0
Samara
Query!
Country [125]
0
0
Russian Federation
Query!
State/province [125]
0
0
Saratov
Query!
Country [126]
0
0
Russian Federation
Query!
State/province [126]
0
0
St-Petersburg
Query!
Country [127]
0
0
Russian Federation
Query!
State/province [127]
0
0
St. Petersburg
Query!
Country [128]
0
0
Russian Federation
Query!
State/province [128]
0
0
Tomsk
Query!
Country [129]
0
0
Russian Federation
Query!
State/province [129]
0
0
Voronezh
Query!
Country [130]
0
0
South Africa
Query!
State/province [130]
0
0
Cap Town
Query!
Country [131]
0
0
South Africa
Query!
State/province [131]
0
0
Cape Town
Query!
Country [132]
0
0
South Africa
Query!
State/province [132]
0
0
Meyerspark
Query!
Country [133]
0
0
South Africa
Query!
State/province [133]
0
0
Port Elizabeth
Query!
Country [134]
0
0
South Africa
Query!
State/province [134]
0
0
Pretoria
Query!
Country [135]
0
0
South Africa
Query!
State/province [135]
0
0
Somerset West
Query!
Country [136]
0
0
South Africa
Query!
State/province [136]
0
0
Soweto
Query!
Country [137]
0
0
Spain
Query!
State/province [137]
0
0
Barcelona
Query!
Country [138]
0
0
Spain
Query!
State/province [138]
0
0
Granada
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Hostalets De Balenyà
Query!
Country [140]
0
0
Spain
Query!
State/province [140]
0
0
La Coruña
Query!
Country [141]
0
0
Spain
Query!
State/province [141]
0
0
Lugo
Query!
Country [142]
0
0
Spain
Query!
State/province [142]
0
0
Madrid
Query!
Country [143]
0
0
Spain
Query!
State/province [143]
0
0
Palma De Mallorca
Query!
Country [144]
0
0
Spain
Query!
State/province [144]
0
0
Quart De Poblet
Query!
Country [145]
0
0
Spain
Query!
State/province [145]
0
0
Sant Joan Despí
Query!
Country [146]
0
0
Spain
Query!
State/province [146]
0
0
Sevilla
Query!
Country [147]
0
0
Sweden
Query!
State/province [147]
0
0
Ljungby
Query!
Country [148]
0
0
Sweden
Query!
State/province [148]
0
0
Malmö
Query!
Country [149]
0
0
Sweden
Query!
State/province [149]
0
0
Rättvik
Query!
Country [150]
0
0
Sweden
Query!
State/province [150]
0
0
Stockholm
Query!
Country [151]
0
0
Sweden
Query!
State/province [151]
0
0
Vällingby
Query!
Country [152]
0
0
Ukraine
Query!
State/province [152]
0
0
Chernivtsi
Query!
Country [153]
0
0
Ukraine
Query!
State/province [153]
0
0
Ivano-Frankovsk
Query!
Country [154]
0
0
Ukraine
Query!
State/province [154]
0
0
Kyiv
Query!
Country [155]
0
0
Ukraine
Query!
State/province [155]
0
0
Lviv
Query!
Country [156]
0
0
Ukraine
Query!
State/province [156]
0
0
Vinnytsya
Query!
Country [157]
0
0
United Kingdom
Query!
State/province [157]
0
0
Coventry
Query!
Country [158]
0
0
United Kingdom
Query!
State/province [158]
0
0
Dundee
Query!
Country [159]
0
0
United Kingdom
Query!
State/province [159]
0
0
Guildford
Query!
Country [160]
0
0
United Kingdom
Query!
State/province [160]
0
0
Leicester
Query!
Country [161]
0
0
United Kingdom
Query!
State/province [161]
0
0
Norwich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone
and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c)
change from baseline to Week 30.
Secondary Objective:
To compare the overall efficacy and safety of insulin glargine/lixisenatide fixed ratio
combination (FRC) to insulin glargine alone and to lixisenatide alone (on top of metformin
treatment) over a 30 week treatment period in participants with type 2 diabetes.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02058147
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02058147
Download to PDF